Pexa-Vec the main prize in SillaJen's Jennerex acquisition
This article was originally published in Scrip
SillaJen, a South Korean contract R&D services group, has signed a definitive agreement to acquire the private US oncolytic immunotherapy venture Jennerex in an all-cash transaction worth up to $150m including future milestone payments.
You may also be interested in...
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.